Review
Open access
Oct 2026
Senolytic therapy in Alzheimer’s disease: clinical evidence and biomarkers
The advancement of controlled clinical studies, combined with the use of molecular biomarkers, neuroimaging, and longitudinal cognitive assessment, may clarify the impact of these interventions on disease progression and contribute to the development of more targeted and safer therapies.
Camilla Rodrigues Pereira da Silva, Ana Beatriz Balão, Beatriz de Lima Soares et al.
· ANPAbstract_CBN26 · 0 citations